Kang Wen, Liu Zheng-Wen, Han Qun-Ying, Zhang Lei, Lei Yan, Lou Sai
Department of Infectious Diseases, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an 710061, China.
Zhonghua Yi Xue Za Zhi. 2008 Apr 8;88(14):980-4.
To explore the effects of granulocyte colony- stimulating factor (G-CSF) on hepatocyte apoptosis in acute liver failure (ALF) and possible mechanism thereof.
One hundred and sixty SD rats underwent intraperitoneal injection of D-galactosamine (D-GalN) 1.4 g/kg so as to establish AFL models and then were randomly divided into 2 equal groups: G-CSF therapy group, injected hypodermically with recombinant human G-CSF 50 microg x kg(-1) x d(-1) 2 hours after D-GalN injection for 3 consecutive days, and placebo control group, injected hypodermically with normal saline for 3 consecutive days. Liver samples were collected from 6 rats of each group 6 h, 12 h, 1 day, and 3 days after D-GalN injection respectively. Another six normal rats were used as normal control group. Hepatocyte apoptosis rate was measured by flow cytometry. Immunohistochemistry was used to detect the expression of Bcl-2 and caspase-3, a proapoptosis protein, in the liver sections.
The survival rate of the G-CSF therapy group was 53.3%, significantly higher than that of the placebo control group (33.3%, P = 0.027). The hepatocyte apoptosis rate and expression rates of Bcl-2 and caspase-3 in the liver sections after D-GalN injection increased along with time. The hepatocyte apoptosis rate peaked 1 day after the D-GalN injection in both groups. The maximum hepatocyte apoptosis rate of the G-CSF group was 29% +/- 7%, significantly lower than that of the placebo control group (44% +/- 12%, P = 0.026). The gray scale of Bcl-2 in liver sections at hour 12 of the G-CSF group was 152 +/- 37, significantly lower than that of the placebo control group (161 +/- 7, P = 0.012). and the gray scale of Bcl-2 on day 1 of the G-CSF group was 150 +/- 12, significantly lower than that of the placebo control group (159 +/- 9, P = 0.018). The gray scales of caspase-3 on days 1 and 3 of the G-CSF group were 189.6 +/- 4.6 and 184.7 +/- 4.8 respectively, both significantly higher than those of the placebo control group (169.6 +/- 15.7 and 160.0 +/- 5.0, both P = 0.000).
Apoptosis is a key mechanism contributing to ALF. G-CSF prevents ALF induced by D-GalN, thus raising the survival rate. G-GSF shows an inhibitory efficacy on hepatocytes apoptosis by probably up-regulating Bcl-2 and reducing caspase-3 expression.
探讨粒细胞集落刺激因子(G-CSF)对急性肝衰竭(ALF)时肝细胞凋亡的影响及其可能机制。
160只SD大鼠腹腔注射1.4 g/kg D-半乳糖胺(D-GalN)建立急性肝衰竭模型,然后随机分为2组,每组80只:G-CSF治疗组于注射D-GalN 2小时后皮下注射重组人G-CSF 50 μg·kg⁻¹·d⁻¹,连续3天;安慰剂对照组皮下注射生理盐水,连续3天。分别于注射D-GalN后6小时、12小时、1天和3天每组各取6只大鼠留取肝组织样本。另取6只正常大鼠作为正常对照组。采用流式细胞术检测肝细胞凋亡率。免疫组化法检测肝组织切片中抗凋亡蛋白Bcl-2和促凋亡蛋白caspase-3的表达。
G-CSF治疗组存活率为53.3%,明显高于安慰剂对照组(33.3%,P = 0.027)。注射D-GalN后肝组织中肝细胞凋亡率以及Bcl-2和caspase-3表达率均随时间增加。两组肝细胞凋亡率均在注射D-GalN后1天达到峰值。G-CSF组最大肝细胞凋亡率为29%±7%,明显低于安慰剂对照组(44%±12%,P = 0.026)。G-CSF组12小时肝组织切片中Bcl-2灰度值为152±37,明显低于安慰剂对照组(161±7,P = 0.012);G-CSF组1天时Bcl-2灰度值为150±12,明显低于安慰剂对照组(159±9,P = 0.018)。G-CSF组1天和3天时caspase-3灰度值分别为189.6±4.6和184.7±4.8,均明显高于安慰剂对照组(169.6±15.7和160.0±5.0,P值均为0.000)。
凋亡是急性肝衰竭发生的关键机制。G-CSF可预防D-GalN诱导的急性肝衰竭,从而提高存活率。G-CSF可能通过上调Bcl-2表达、降低caspase-3表达而对肝细胞凋亡具有抑制作用。